Activity of pentamidine-loaded poly (D,L-lactide) nanoparticles against Leishmania infantum in a murine model

Parasite

Volumn 4, Issue 4, 1997, Pages 331-336

  Durand, R ^a   Paul, M ^b   Rivollet, D ^a   Fessi, H ^c   Houin, R ^a   Astier, A ^b   Deniau, M ^a  

^a FACULTÉ DE MÉDECINE   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

Effective doses; Leishmania infantum; Mouse model; Pentamidine; Poly D,L lactide nanoparticles; Visceral leishmaniasis

Indexed keywords

LEISHMANIA INFANTUM; MURINAE;

ANTIPROTOZOAL AGENT; PENTAMIDINE; POLYESTER; POLYLACTIDE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; DELAYED RELEASE FORMULATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; LEISHMANIA INFANTUM; MOUSE; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; PENTAMIDINE; POLYESTERS;

EID: 0031311892     PISSN: 1252607X     EISSN: None     Source Type: Journal    
DOI: 10.1051/parasite/1997044331     Document Type: Article

References (25)

1. ANTOINE J.C., PRINA E., JOUANNE C. & BONGRAND P. Parasitophorous vacuoles of Leishmania amazonensis- infected macrophages maintain an acidic pH. Infection and Immunity, 1990, 58, 779-787.
2. ASTIER A., DOAT B., FERRER M.J., BENOIT G., FLEURY J., ROLLAND A. & LEVERGE R. Enhancement of Adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U937 cells. Cancer Research, 1988, 48, 1835-1841.
3. 14C-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials, 1992, 13, 1493-1102.
4. BERMAN J.D., GALLALEE J.S., WILLIAMS J.S. & HOCKMEYER D. Activity of pentamidine-containing human red cell ghosts against visceral leishmaniasis in the hamster. American Journal of Tropical Medicine and Hygiene, 1986, 35 297-302.
5. DAVIDSON R.N., DI MARTINO L., GRADONI L., GIACCHINO R., GAETA G.B., PEMPINELLO R., SCOTTI S., CASCIO A., CASTAGNOLA E., MAISTO A., GRAMICCIA M., DI CAPRIO D., WILKINSON R.J. & BRYCESON A.D.M. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clinical Infectious Diseases, 1996, 22, 938-943.
6. DEBS J., STRAUBINGER R.M., BRUNETTE E.N., LIN J.M., LIN E.M., MONTGOMERY A.B., FRIEND D.S. & PAPAHADJOPOULOS D.P. Selective enhancement of pentamidine uptake in the lung by aerosolization and delivery in liposomes. American Review of Respiratory Diseases, 1987, 135, 731-737.
7. DESJEUX P. Leishmaniasis, Public Health aspects and control. Clinics in Dermatology, 1996, 14, 417-423.
8. DURAND, R., PAUL M., RIVOLLET D., HOUIN R., ASTIER. A. & DENIAU M. Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model. International Journal for Parasitology, in press.
9. FATTAL E., YOUSSEF M., COUVREUR P. & ANDREMONT A. Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. Antimicrobial Agents and Chemotherapy, 1989, 33, 1540-1543.
10. FESSI H., STAINMESSE S., DEVISSAGUET J.P. & PUISIEUX F. 1988. Fr. Patent 8, 808, 874.
11. GRADONI L., BRYCESON A. & DESJEUX P. Treatment of Mediterranean visceral leishmaniasis. Bulletin of the World Health Organization, 1995, 73, 191-197.
12. HIEMENZ J.W. & WALSH T.J. Lipid formulations of amphotericin B: recent progress and future directions. Clinical Infectious Diseases, 1996, 22 (Suppl. 2), 133-144.
13. LEWIS D.H. Controlled release of bioactive agents from lactide/glycolyde polymers, in: Chasin M. & Langer R. (eds), biodegradable polymers as delivery system, Marcell Decker, New York, 1990, 1-41.
14. MAKINO K., ARAKAWA M. & KONDO T. Preparation and in vitro degradation properties of polylactide microcapsules. Chemical Pharmaceutical Bulletin, 1985, 33, 1195-1201.
15. MODABBER F. Leishmaniasis, in: Tropical Disease Research progress 91-92, eleventh program report (edited by Maurice J. & Pierce A.M.), World Health Organization, Geneva, 1992, 77-81.
16. NEAL R.A., CROFT S.L. & NELSON D.J. Antileishmanial effect of allopurinol ribonucleoside and the related compounds, allopurinol, thiopurinol, ribonucleotide and of fomiycin B, sinefugin and the lepidine WR 6026. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1985, 79, 122-128.
17. NEAL R.A., Experimental chemotherapy, in: The leishmaniasis in biology and medicine (edited by Peters W. & Killick-Kendrick R.), London Academic press, London, 1987, 793-845.
18. NEW R.R. & CHANCE M.L. Treatment of experimental cutaneous leishmaniasis by liposome-entrapped pentostam. Acta Tropica, 1980, 37, 253-256.
19. PAUL M., DURAND R, BOULARD Y., FUSAÏ T., FERNANDEZ C., RIVOLLET D., DENIAU M. & ASTIER A. Physicochemical characteristcs of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice. Journal of Drug Targeting, in press.
20. RODRIGUES J.M., CROFT S.L., FESSI H., BORIES C. & DEVISSAGUET J.P. The activity and ultrastructural localization of primaquine-loaded poly (d,l-lactide) nanoparticles in Leishmania donovani infected mice. Tropical Medicine and Parasitology, 1994, 45, 223-228.
21. RODRIGUES J.M., FESSI H., BORIES C., PUISIEUX F. & DEVISSAGUET J.P. Primaquine-loaded poly(lactide)nanoparticles: physicochemical study and acute tolerance in mice. International Journal of Pharmaceutics, 1995, 126, 253-260.
22. ROSENTHAL E., MARTY P., POIZOT-MARTIN I., REYNES J., PRATLONG F., LAFEUILLADE A., JAUBERT D., BOULAT O., DEREURE J. & GAMBARELLI F. Visceral leishmaniasis and HIV-1 co-infection in southern France. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 159-162.
23. STAUBER L.A., FRANCHINO E.M. & GRUN J. An eight-day method for screening compounds against Leishmania donovani in golden hamsters. Journal of Protozoology, 1958, 5, 269-273.
24. TORRE-CISNEROS J., VILLANUEVA J.L,. KINDELAN J.M., JURADO R. & SANCHEZ-GUIJO P. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clinical Infectious Diseases, 1993, 17, 625-627.
25. VENIER-JULIENNE M.C., VOULDOUKIS I., MONJOUR L. & BENOIT J.P. In vitro study of the antileishmanial activity of biodegradable nanoparticles. Journal of Drug Targeting, 1995, 3, 23-29.